Discover
SLN
Silence Therapeutics plc
10.50
2 x 7.90
2 x 13.26
bid
ask
-
0.48
4.37%
2 @ 04:00 PM
10.18 -0.32 (3.05%)
| Ytd | 72.70% | |
| 1y | 77.36% |
10.22
day range
11.06
4.19
52 week range
11.06
| Open | 10.82 | Prev Close | 10.98 | Low | 10.22 | High | 11.06 | Mkt Cap | 495.96M |
| Vol | 717.51K | Avg Vol | 389.77K | EPS | -1.62 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.29 | Short Ratio | 2.36 | Inst. Own | 62.77% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 7.28 | 200-d Avg | 6.27 | 1yr Est | 53.70 |
SLN News
zacks.com
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher
benzinga.com
This $300 Million Biotech May Be Deeply Mispriced: Analyst
Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major
benzinga.com
Cantor Fitzgerald Initiates Coverage On Silence Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Silence Therapeutics (NASDAQ:SLN)
benzinga.com
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Sess
U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls afte
benzinga.com
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN)
benzinga.com
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d
benzinga.com
Silence Therapeutics Presents Follow-Up, Quality-Of-Life Data From Phase 1 SANRECO Study Evaluating
New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and qu